logo
Sign InSign Up

REVVITY INC (RVTY)

Sector: Healthcare

Financial Fundamentals

findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for RVTY, sign up here.

Income Statement

Revenue

$2.8bn

Gross Profit

$1.5bn

Earning before Tax

$696.6m

Net Income

$693.1m

Net Income Common Shareholders

$693.1m

EPS

5.56

Balance Sheet

Cash

$913.2m

Debt

$4.0bn

Assets

$13.6bn

Liabilities

$5.7bn

Equity

$7.9bn

Enterprise Value

$16.4bn

Cash Flow Statement

Net Cash from Operations

$91.3m

Net Cash from Investing

$1.3bn

Net Cash from Financing

$-0.9bn

Net Cash Flow

$443.6m

Free Cash Flow

$9.9m

Free Cash Flow per Share

$0.08

Metrics

Price to Equity

19.46

Price to Equity (Damodaran)

19.66

Price to Book

1.71

Net Margin

0.25

Return on Equity

0.09

Return on Sales

0.30

Get immediate access to 5-years of reference grade data for RVTY for free.

Sign up

Company Profile

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Company Info

Industry

Diagnostics & Research

Employees

11,000

Address

940 Winter Street
Waltham, MA 02451
United States

Phone

781 663 6900

Last Updated

2024-02-15

Available Data

Standardized Financial Statements

EOD Price History

Corporate Actions

Institutional Holdings

Insider Transactions

Sign up for free and get immediate access
logo

Radically accessible financial data

Contact Info

findl.com info@findl.com

Explore findl data

DocumentationSupport

Copyright © findl 2024. All rights reserved.

Terms & Use

Privacy Policy